MERLIN-TIMI 36

MERLIN-TIMI 36 evaluated a novel anti-ischemic agent, ranolazine, in patients with acute coronary syndromes.

DOWNLOAD SLIDE SET (PDF)

Key Study Publications

Morrow, D. A., Scirica, B. M., Karwatowska-Prokopczuk, E., Murphy, S. A., Budaj, A., Varshavsky, S., Wolff, A. A., Skene, A., McCabe, C. H., Braunwald, E. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA. 2007;297(16):1775-83. Abstract